Extendicare (TSX:EXE) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:EXE Extendicare Inc TSX:EXE
79 GF Score
Price C$37.33
GF Value C$14.21
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Extendicare Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Extendicare is: Low Risk: Strong fundamentals, worth long-term holding.

Extendicare  (TSX:EXE) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Extendicare Risk Assessment Related Terms

TSX:EXE vs HCA, THC, DVA: Risk Assessment Comparison

For the Medical Care Facilities subindustry, Extendicare's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Extendicare Risk Assessment vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Extendicare's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Extendicare's Risk Assessment falls into.


TSX:EXE
79GF Score
Extendicare Inc TSX:EXE
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Extendicare (TSX:EXE) Overvalued in 2026?

Based on GuruFocus' analysis, Extendicare stock appears to be overvalued. The current stock price of C$37.33 is trading 162.7% above its estimated GF Value™ of C$14.21. GuruFocus considers Extendicare to be Significantly Overvalued.

Key valuation signals for TSX:EXE:

  • Risk Assessment:
  • GF Value™: C$14.21 vs. price of C$37.33 (162.7% above fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the TSX:EXE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Extendicare Business Description

Other Exchanges EXETF:USA0S9E:UK5XE:Germany
Address 3000 Steeles Avenue East, Suite 400, Markham, ON, CAN, L3R 4T9
Extendicare Inc is a senior care provider in Canada, focused on long-term care and home health care. The has three main business segments: Long-term Care (LTC), Home Health Care, and Managed Services. The Long-term Care segment, operating under the Extendicare brand, represents 53 owned homes in Ontario, Alberta and Manitoba. The Home Health Care segment, operating under the ParaMed brand, provides home health care services annually in Ontario, Alberta, Manitoba and Nova Scotia. The Managed Services segment, operating under the Extendicare Assist and SGP Purchasing Partner Network brands, provides management, consulting and group purchasing services to other care providers across Canada. The majority of the company's revenue is derived from the Long-term Care segment.
79GF Score

Get the complete analysis for TSX:EXE

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$37.33
Price
C$14.21
GF Value